Amgen vs Meta: Founders, CEOs and History
Amgen was founded in 1980 by George B. Rathmann, William K. Bowes Jr. and is led by Robert A. Bradway. Meta was founded in 2004 by Mark Zuckerberg, Eduardo Saverin, Andrew McCollum and is led by Mark Zuckerberg.
Company facts
Founders
Amgen
George B. Rathmann
Amgen, originally incorporated as Applied Molecular Genetics, was founded in 1980 not by a single scientist, but by a calculated syndicate of venture capitalists and academics trying to commercialize the brand-new science of recombinant DNA.
William K. Bowes Jr.
William K. Bowes Jr. Was the venture capital strategist whose vision catalyzed Amgen's formation.
Meta
Mark Zuckerberg
Meta possesses arguably the most scrutinized, polarizing, and dramatized founding story of the 21st century, rooted entirely in the exclusive, intensely competitive dormitory culture of Harvard University and driven by an effective, socially awkward computer p…
Eduardo Saverin
Eduardo Saverin was a Facebook co-founder and the company's first chief financial officer, but his long-term story diverged sharply from the company he helped start.
Andrew McCollum
Andrew McCollum co-founded Facebook but left the company relatively early compared with Zuckerberg and Moskovitz. After Facebook, he continued in technology and entrepreneurship, including work connected to education and startup leadership.
Dustin Moskovitz
Dustin Moskovitz co-founded Facebook and served as a key early technical and operational leader before leaving in 2008 to co-found Asana.
Chris Hughes
Chris Hughes co-founded Facebook and later became known for his work in media, politics, and public policy after leaving the company.
CEOs and their tenures
Amgen
- George B. Rathmann1980–1988
Chief Executive Officer
George Rathmann, a physical chemist who had run research and development at Abbott Laboratories, was named Amgen's first chief executive in 1980 and worked from a small trailer so that laboratory space could go to scientists.
Source - Gordon M. Binder1988–2000
Chief Executive Officer
Gordon Binder joined Amgen as chief financial officer in 1982 and led its June 1983 initial public offering.
Source - Kevin W. Sharer2000–2012
Chief Executive Officer
Kevin Sharer joined Amgen in 1992 as president and chief operating officer and became chairman and chief executive in 2000.
Source - Robert A. Bradway2012–present
Chairman and Chief Executive Officer
Robert Bradway became chief executive on May 23, 2012, succeeding Kevin Sharer as the fourth CEO in Amgen's history, and added the chairmanship at the start of 2013.
Source
Meta
- Mark Zuckerberg2004–present
Founder, Chairman and CEO
Zuckerberg sets product and capital priorities and controls the majority of shareholder voting power through Class B shares.
Source - Eduardo Saverin2004–2005
Co-Founder
Eduardo Saverin co-founded Facebook with Mark Zuckerberg while at Harvard in 2004, providing the initial seed funding and serving as the company's first CFO and business manager.
Source
Timeline: Amgen and Meta side by side
1980Amgen
Applied Molecular Genetics is incorporated
Applied Molecular Genetics (AMGen) was incorporated on April 8, 1980 in Thousand Oaks, California, as the idea of venture capitalist William K. Bowes Jr. and a group of scientific collaborators.
1983Amgen
Nasdaq listing and the erythropoietin clone
Amgen completed its initial public offering on June 17, 1983, raising nearly US$40 million under chief financial officer Gordon Binder, and formally shortened its name to Amgen.
1984Amgen
Kirin-Amgen joint venture formed
Amgen and Kirin Brewery Company of Japan formed Kirin-Amgen in 1984 as a joint venture for the worldwide commercialization of erythropoietin.
1985Amgen
G-CSF cloned, leading to Neupogen
While Fu-Kuen Lin's team worked on erythropoietin, researcher Larry Souza and his group cloned and expressed human granulocyte colony-stimulating factor in 1985.
1989Amgen
FDA approves Epogen
The FDA approved Epogen (epoetin alfa) on June 1, 1989 for anemia in patients with chronic kidney failure on dialysis. It was the first commercial recombinant human erythropoietin. Epogen's U.S.
1991Amgen
Neupogen approved, giving Amgen a second franchise
The FDA approved Neupogen (filgrastim) in February 1991. By stimulating white blood cell production it reduced the risk of infection in cancer patients with chemotherapy-induced neutropenia.
1991Amgen
Amgen wins the erythropoietin patent fight
On March 6, 1991 the U.S. Court of Appeals for the Federal Circuit upheld the Kirin-Amgen erythropoietin patent and ruled against Genetics Institute in Amgen v. Chugai Pharmaceutical and Genetics Institute.
2001Amgen
FDA approves Aranesp, the longer-acting EPO
Aranesp (darbepoetin alfa), an erythropoietin analogue with modified glycosylation and a longer half-life, was approved in 2001. Less frequent dosing than Epogen improved convenience and gave Amgen a newer, higher-priced product to migrate patients toward.
2002Amgen
US$16 billion Immunex acquisition brings Enbrel in-house
Amgen completed its acquisition of Immunex Corporation on July 16, 2002, the largest biotechnology deal to that point at about US$16 billion in stock and cash.
2004Meta
Facebook launches at Harvard
Facebook launched on February 4, 2004, as a real-name student network. The product mattered because it made identity, campus trust and friend connections the core of the service before the company became a public social platform.
2007Meta
Ad platform becomes the business model
Facebook's advertising products turned user attention into a scalable commercial system. The shift mattered because the company could keep the consumer product free while charging marketers for measurable reach, targeting and conversion tools.
2010Amgen
Prolia and XGEVA create the bone health franchise
The FDA approved Prolia (denosumab) for postmenopausal osteoporosis in June 2010 and XGEVA, the same molecule at a higher dose, for prevention of skeletal-related events in cancer patients in November 2010.
2012Meta
Instagram acquisition
Facebook agreed to acquire Instagram for about $1 billion in cash and stock. The deal mattered because Instagram was mobile-native at a moment when Facebook needed to prove it could survive the smartphone shift.
2012Meta
Facebook IPO
Facebook completed its initial public offering in May 2012, raising about $16 billion.
2014Meta
WhatsApp acquisition
Facebook announced a deal to acquire WhatsApp, adding a large private messaging network to a company still known mainly for public feeds.
2014Meta
Oculus acquisition
Facebook agreed to acquire Oculus VR for about $2 billion. The deal mattered because it gave the company a hardware and immersive-computing bet years before the Meta rebrand.
2019Amgen
US$13.4 billion purchase of Otezla from Celgene
Amgen agreed in August 2019 to buy worldwide rights to Otezla (apremilast) from Celgene for US$13.4 billion in cash, or about US$11.2 billion net of the present value of US$2.2 billion of anticipated future cash tax benefits, and closed on November 21, 2019.
2020Amgen
Amgen joins the Dow Jones Industrial Average
Amgen replaced Pfizer in the Dow Jones Industrial Average on August 31, 2020, becoming one of the thirty components in the index. Inclusion recognized the scale Amgen had reached and added passive demand from Dow-tracking funds.
2021Meta
Facebook becomes Meta
Facebook changed its corporate name to Meta in 2021 to bring its apps and technologies under a new company brand.
2023Amgen
US$27.8 billion Horizon Therapeutics acquisition closes
Amgen completed the acquisition of Horizon Therapeutics plc on October 6, 2023 for US$116.50 per share in cash, an equity value of about US$27.8 billion, after settling FTC litigation with a behavioral consent decree.
2023Meta
Threads launch
Meta launched Threads in July 2023 and said the app passed 100 million sign-ups in its first five days. The launch mattered because Instagram distribution gave Meta a fast entry into real-time text conversation.
2024Amgen
Imdelltra becomes the first T-cell engager for small cell lung cancer
The FDA granted accelerated approval to tarlatamab, sold as Imdelltra, on May 16, 2024 for extensive stage small cell lung cancer that has progressed on or after platinum-based chemotherapy.
2024Meta
$164.501B revenue
Meta reported $164.501 billion in FY2024 revenue and $62.360 billion in net income. The year mattered because AI-powered ad tools, Reels monetization and expense discipline restored confidence after the 2022 slowdown.
2025Amgen
VESALIUS-CV extends the Repatha case to primary prevention
In November 2025 Amgen reported Phase 3 VESALIUS-CV results in more than 12,000 patients with atherosclerosis or diabetes but no prior heart attack or stroke.
2025Meta
$200.966B Revenue
Meta reported $200.966B in FY2025 revenue, $60.458B in net income, $83.276B in income from operations, and 78,865 employees at year-end.
2026Amgen
Medicare price setting reaches Enbrel and Otezla
Enbrel's negotiated Medicare price under the Inflation Reduction Act took effect on January 1, 2026, after it was named in the first round of ten drugs selected for negotiation.
2026Meta
Q2 2026 revenue up 28%
Meta reported Q2 2026 revenue of $60.80B, up 28%, and net income of $15.85B, down 14%, after $2.40B of legal charges and $1.18B of severance from a May 2026 headcount reduction. It narrowed 2026 capex guidance to $130-145B.
Acquisitions
Amgen
- Horizon Therapeutics plc2023$27.8B
- ChemoCentryx, Inc.2022$3.7B
- Five Prime Therapeutics2021$1.9B
- Celgene Otezla Business2019$13.4B
- Onyx Pharmaceuticals, Inc.2013$10.4B
- DeCODE Genetics2012$415M
Meta
- Kustomer2022$1B
- CTRL-labs2019$500M
- WhatsApp2014$19B
- Oculus VR2014$2B
- Instagram2012$1B
Questions about Amgen vs Meta
Who is the CEO of Amgen Inc. and Meta Platforms, Inc.?
Amgen Inc. is led by Robert A. Bradway and Meta Platforms, Inc. is led by Mark Zuckerberg. Both serve as the top executive responsible for the company's strategy, operations, and financial performance.
When was Amgen Inc. founded vs Meta Platforms, Inc.?
Amgen Inc. was founded in 1980 — 24 years before Meta Platforms, Inc., which was founded in 2004. Amgen Inc.'s longer operating history gives it a deeper track record but also potentially more institutional inertia compared to the younger Meta Platforms, Inc..
How many employees does Amgen Inc. have compared to Meta Platforms, Inc.?
Amgen Inc. employs approximately 31,500 people, while Meta Platforms, Inc. employs approximately 75,472. Meta Platforms, Inc. has the larger workforce at 75,472 employees, compared to Amgen Inc.'s 31,500. A higher headcount does not necessarily imply greater efficiency — it often reflects differences in business model (e.g., manufacturing vs. software).
Where are Amgen Inc. and Meta Platforms, Inc. headquartered?
Both Amgen Inc. and Meta Platforms, Inc. are headquartered in United States, meaning they operate under the same primary regulatory and tax environment.
Who founded Amgen Inc. and Meta Platforms, Inc.?
Amgen Inc. was founded by George B. Rathmann, William K. Bowes Jr.. Meta Platforms, Inc. was founded by Mark Zuckerberg, Eduardo Saverin, Andrew McCollum, Dustin Moskovitz, Chris Hughes.
Which company has a longer operating history — Amgen Inc. or Meta Platforms, Inc.?
Amgen Inc. has been operating for approximately 46 years, making it the more established of the two companies. Meta Platforms, Inc. has been in operation for around 22 years. A longer operating history often signals greater institutional resilience and brand recognition, though it can also mean slower adaptation to new market conditions.
Figures come from each company's filings and the sources linked beside them. Amounts reported in another currency are shown in US dollars at an approximate rate and marked with ~. Back to the Amgen vs Meta overview